文献速递心律失常心力衰竭与心肌病

黑人与白人患者接受一级预防除颤器的房性及室性心律失常与生存结局对比

Arrhythmia and Survival Outcomes Among Black Patients and White Patients With a Primary Prevention Defibrillator.
PubMed 文献 · Circulation · 2023-07-17

本研究纳入美国3895例接受一级预防性ICD植入的患者,比较自我报告的黑人与白人患者(缺血性与非缺血性心肌病)在室性心动过速(VTA)、房性心动过速(ATA)、ICD治疗及死亡方面的差异。在非缺血性心肌病中,黑人患者VTA、ATA、恰当及不恰当ICD治疗的发生率均显著更高,死亡风险也更高;但在缺血性心肌病中两组无差异。两组患者从ICD植入中获得的总体获益相似。

要点

  • 非缺血性心肌病黑人患者VTA≥170 bpm发生率为32% vs 20%,VTA≥200 bpm为22% vs 14%。
  • 非缺血性心肌病黑人患者ATA、恰当及不恰当ICD治疗均显著高于白人。
  • 缺血性心肌病中黑人与白人患者的室速及死亡风险无显著差异。

核心结论

  • 在非缺血性心肌病一级预防ICD患者中,黑人患者较白人患者有更高的VTA、ATA及ICD治疗风险和负荷,生存率更低。
  • 然而,ICD的总体获益得以维持且与白人患者相似。

研究设计与样本

  • 研究人群为美国3895例参加一级预防ICD试验的ICD接受者。
  • 所有事件均采用盲法裁定。
  • 比较自我报告的黑人患者与白人患者(缺血性和非缺血性心肌病)的结局。

主要发现

  • 非缺血性心肌病黑人患者VTA≥170 bpm发生率为32% vs 20%,VTA≥200 bpm为22% vs 14%,ATA为25% vs 12%,恰当治疗为30% vs 20%,不恰当治疗为25% vs 11%(P<0.001)。
  • 多变量分析显示非缺血性心肌病黑人患者所有类型心律失常或ICD治疗风险更高:VTA≥170 bpm HR 1.71,VTA≥200 bpm HR 1.58,ATA HR 1.87,恰当治疗HR 1.62,不恰当治疗HR 1.86(P≤0.01)。
  • 非缺血性心肌病黑人患者VTA负荷HR 1.84,恰当治疗负荷HR 1.84(P<0.001),死亡风险HR 1.92(P=0.014)。
  • 缺血性心肌病中黑人与白人患者所有类型室速、ICD治疗或死亡风险相似。
  • 两组患者从ICD植入中获得的获益显著且相似。

关键数值与推荐

  • 非缺血性心肌病黑人患者VTA≥170 bpm发生率为32% vs 20%。
  • 非缺血性心肌病黑人患者VTA≥200 bpm发生率为22% vs 14%。
  • 非缺血性心肌病黑人患者ATA发生率为25% vs 12%。
  • 非缺血性心肌病黑人患者恰当治疗为30% vs 20%,不恰当治疗为25% vs 11%。
  • 多变量分析中非缺血性心肌病黑人患者VTA≥170 bpm的HR为1.71,死亡HR为1.92。

临床怎么用

  • 对于非缺血性心肌病黑人患者,应认识到其更高的室性及房性心律失常风险和ICD治疗需求。
  • 尽管风险更高,ICD植入的总体获益仍与白人患者相似,支持在这一人群中继续合理使用ICD进行一级预防。
  • 需要针对非缺血性心肌病黑人患者优化心律失常监测与管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Black Americans have a higher risk of nonischemic cardiomyopathy (NICM) than White Americans. We aimed to evaluate differences in the risk of tachyarrhythmias among patients with an implantable cardioverter-defibrillator (ICD). METHODS: The study population comprised 3895 ICD recipients in the United States enrolled in primary prevention ICD trials. Outcome measures included ventricular tachyarrhythmia (VTA), atrial tachyarrhythmia (ATA), ICD therapies, VTA burden (using Andersen-Gill recurrent event analysis), death, and the predicted benefit of the ICD. All events were adjudicated blindly. Outcomes were compared between self-reported Black patients versus White patients with cardiomyopathy (ischemic and NICM). RESULTS: Black patients were more likely to be female (35% versus 22%) and younger (57±12 versus 62±12 years) with a higher frequency of comorbidities. In NICM, Black patients had a higher rate of first VTA, fast VTA, ATA, and appropriate and inappropriate ICD therapy (VTA ≥170 bpm, 32% versus 20%; VTA ≥200 bpm, 22% versus 14%; ATA, 25% versus 12%; appropriate therapy, 30% versus 20%; and inappropriate therapy, 25% versus 11%; P<0.001 for all). Multivariable analysis showed that Black patients with NICM experienced a higher risk of all types of arrhythmia or ICD therapy (VTA ≥170 bpm, hazard ratio [HR] 1.71; VTA ≥200 bpm, HR 1.58; ATA, HR 1.87; appropriate therapy, HR 1.62; inappropriate therapy, HR 1.86; P≤0.01 for all), higher burden of tachyarrhythmias or therapies (VTA, HR 1.84; appropriate therapy, HR 1.84; P<0.001 for both), and a higher risk of death (HR 1.92; P=0.014). In contrast, in ischemic cardiomyopathy, the risk of all types of tachyarrhythmia, ICD therapy, or death was similar between Black patients and White patients. Both Black patients and White patients derived a significant and similar benefit from ICD implantation. CONCLUSIONS: Among patients with NICM with an ICD for primary prevention, Black patients compared with White patients had a high risk and burden of VTA, ATA, and ICD therapies with a lower survival rate. Nevertheless, the overall benefit of the ICD was maintained and was similar to that of White patients.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Younis A, Ali S, Hsich E, et al. Arrhythmia and Survival Outcomes Among Black Patients and White Patients With a Primary Prevention Defibrillator. Circulation. 2023. PMID: 37459413. doi:10.1161/CIRCULATIONAHA.123.065367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。